The combination strategy, with the BRAF inhibitor dabrafenib plus MEK inhibitor trametinib, demonstrated promising efficacy in patients with recurrent or refractory BRAF exon 15 p.V600E-mutated high-grade and low-grade gliomas. This evidence concerns the gene BRAF and central nervous system cancer.